Quince Therapeutics Inc (QNCX) USD0.001 B

Sell:$1.50Buy:$1.53$0.04 (2.58%)

NASDAQ:0.46%
Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.53
Change:$0.04 (2.58%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.53
Change:$0.04 (2.58%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Key people

Charles S. Ryan
President
Dirk Thye
Chief Executive Officer, Chief Medical Officer, Director
Brendan Hannah
Chief Operating Officer, Chief Business Officer, Principal Financial Officer and Principal Accounting
David A. Lamond
Independent Chairman of the Board
Una Ryan
Lead Independent Director
Luca Benatti
Director
Rajiv Patni
Director
June Bray
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US22053A1079
  • Market cap
    $70.40m
  • Employees
    32
  • Shares in issue
    44.00m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.